Antibodies specific for hyperphosphorylated tau and methods of use thereof
US12129289B2 · kind B2 · utility
0Cited by
50References
15Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Aug 11, 2021 |
| Grant date | Oct 29, 2024 |
| Priority date | — |
| Expiry date | May 29, 2042 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2800/2821
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a class of monoclonal antibody that specifically binds the phosphorylated serine 396 residue on pathological hyperphosphorylated (PHF) tau (pS396) with improved affinity, as well as to methods of using these molecules and their tau binding fragments in the treatment of Alzheimer's disease and other tauopathies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.